190 related articles for article (PubMed ID: 29659383)
41. Prostate penile metastasis: Incidence and imaging pattern on
Tatkovic A; McBean R; Schoeman J; Wong D
J Med Imaging Radiat Oncol; 2020 Aug; 64(4):499-504. PubMed ID: 32449823
[TBL] [Abstract][Full Text] [Related]
42. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
Lin CY; Lee MT; Lin CL; Kao CH
Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
[TBL] [Abstract][Full Text] [Related]
43. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
[TBL] [Abstract][Full Text] [Related]
44. Incidental Meningioma Mimicking Metastasis of Prostate Adenocarcinoma in 68Ga-Labeled PSMA Ligand PET/CT.
Bilgin R; Ergül N; Çermik TF
Clin Nucl Med; 2016 Dec; 41(12):956-958. PubMed ID: 27824323
[TBL] [Abstract][Full Text] [Related]
45. Comparative study between
Wong HS; Leung J; Bartholomeusz D; Sutherland P; Le H; Nottage M; Iankov I; Chang JH
J Med Imaging Radiat Oncol; 2018 Dec; 62(6):816-822. PubMed ID: 30152050
[TBL] [Abstract][Full Text] [Related]
46. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
[TBL] [Abstract][Full Text] [Related]
47. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
[TBL] [Abstract][Full Text] [Related]
48. Nonneoplastic Neuroma After Radical Prostatectomy Is Not a Mimicker of Lymph Node Metastases on 68Ga-PSMA Ligand PET/CT.
Derlin T; Schumacher U; Bengel FM
Clin Nucl Med; 2016 Oct; 41(10):785-6. PubMed ID: 27556791
[TBL] [Abstract][Full Text] [Related]
49. Clinicopathological predictors of positive
Aydin AM; Haberal B; Artykov M; Bilen CY; Yazici S
Ann Nucl Med; 2019 May; 33(5):326-332. PubMed ID: 30778860
[TBL] [Abstract][Full Text] [Related]
50. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
Afaq A; Bomanji J
Br Med Bull; 2018 Dec; 128(1):37-48. PubMed ID: 30272121
[TBL] [Abstract][Full Text] [Related]
51. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report.
Rauscher I; Maurer T; Fendler WP; Sommer WH; Schwaiger M; Eiber M
Cancer Imaging; 2016 Jun; 16(1):14. PubMed ID: 27277843
[TBL] [Abstract][Full Text] [Related]
52.
Kopp J; Kopp D; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz P; Schoerner W; Hammerer P; Schiffmann J
World J Urol; 2020 Dec; 38(12):3085-3090. PubMed ID: 32103332
[TBL] [Abstract][Full Text] [Related]
53. The Utility of 68Ga-PSMA PET/CT in Poorly Differentiated Metastatic Prostate Cancer.
Demirkol MO; Kiremit MC; Acar O; Ucar B; Saglican Y
Clin Nucl Med; 2017 May; 42(5):403-405. PubMed ID: 28319496
[TBL] [Abstract][Full Text] [Related]
54.
Damjanovic J; Janssen JC; Furth C; Diederichs G; Walter T; Amthauer H; Makowski MR
Cancer Imaging; 2018 May; 18(1):20. PubMed ID: 29769114
[TBL] [Abstract][Full Text] [Related]
55. Treatment Outcomes from
Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
[No Abstract] [Full Text] [Related]
56. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
Tulsyan S; Das CJ; Tripathi M; Seth A; Kumar R; Bal C
Nucl Med Commun; 2017 Dec; 38(12):1094-1102. PubMed ID: 28957842
[TBL] [Abstract][Full Text] [Related]
57. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
[TBL] [Abstract][Full Text] [Related]
58. Comparison of
Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
[TBL] [Abstract][Full Text] [Related]
59. Rib Fractures Mimicking Bone Metastases in 18F-PSMA-1007 PET/CT for Prostate Cancer.
Panagiotidis E; Paschali A; Giannoula E; Chatzipavlidou V
Clin Nucl Med; 2019 Jan; 44(1):e46-e48. PubMed ID: 30371591
[TBL] [Abstract][Full Text] [Related]
60. Prostate-Specific Membrane Antigen PET/CT in Splenic Sarcoidosis.
Kobe C; Maintz D; Fischer T; Drzezga A; Chang DH
Clin Nucl Med; 2015 Nov; 40(11):897-8. PubMed ID: 26018688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
